Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy

Hosoda,Kei; Yamashita,Keishi; Ushiku,Hideki; Ema,Akira; Moriya,Hiromitsu; Mieno,Hiroaki; Washio,Marie; Watanabe,Masahiko

doi:10.3892/ol.2017.7515

Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S‑1 chemotherapy

Authors:
- Kei Hosoda
- Keishi Yamashita
- Hideki Ushiku
- Akira Ema
- Hiromitsu Moriya
- Hiroaki Mieno
- Marie Washio
- Masahiko Watanabe
View Affiliations

Affiliations: Department of Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa 252‑0374, Japan
Published online on: December 5, 2017 https://doi.org/10.3892/ol.2017.7515
Pages: 1853-1860

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curative gastrectomy and adjuvant chemotherapy using S‑1 is a standard treatment for stage II/III gastric cancer in Japan. The purpose of the present study was to evaluate the prognostic relevance of fibroblast growth factor receptor (FGFR)2 expression in patients with stage II/III gastric cancer that underwent postoperative adjuvant chemotherapy with S‑1. Formalin‑fixed paraffin‑embedded surgical specimens were retrospectively examined in 167 patients with stage II/III gastric cancer that underwent curative gastrectomy followed by adjuvant S1 chemotherapy. FGFR2 expression was measured using immunohistochemistry (IHC) staining. The IHC results for FGFR2 were as follows: Grade 1+, 32; grade 2+, 80; grade 3+, 55 patients. The FGFR2 expression level was not significantly associated with relapse‑free or overall survival rates. However, in the diffuse type, the FGFR2 expression level tended to be negatively correlated with relapse‑free survival. In particular, the proportion of patients who recurred >5 years following surgery was significantly larger in the FGFR2 grade 3+ group than in the grade 1+, 2+ group (4/22 vs. 1/35; P=0.047). The recurrent sites of long‑term failure were mostly peritoneum among the diffuse type. To the best of our knowledge, the present study indicated for the first time that FGFR2 could predict long‑term failure of adjuvant S‑1 chemotherapy in curative advanced gastric cancer. There was no interaction between FGFR2 expression and patient survival outcomes in stage II/III gastric cancer. Patients with FGFR2 3+ in stage II/III gastric cancer should carefully be followed‑up for >5 years after surgery.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
3	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
4	Goetz R and Mohammadi M: Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 14:166–180. 2013. View Article : Google Scholar : PubMed/NCBI
5	Dedes KJ, Wetterskog D, Ashworth A, Kaye SB and Reis-Filho JS: Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 8:261–271. 2011. View Article : Google Scholar : PubMed/NCBI
6	Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 16:139–149. 2005. View Article : Google Scholar : PubMed/NCBI
7	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
8	Brooks AN, Kilgour E and Smith PD: Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer. Clin Cancer Res. 18:1855–1862. 2012. View Article : Google Scholar : PubMed/NCBI
9	Hattori Y, Odagiri H, Nakatani H, Miyagawa K, Naito K, Sakamoto H, Katoh O, Yoshida T, Sugimura T and Terada M: K-sam, an amplified gene in stomach cancer, is a member of the heparin-binding growth factor receptor genes. Proc Natl Acad Sci USA. 87:pp. 5983–5987. 1990; View Article : Google Scholar : PubMed/NCBI
10	Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, et al: FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer. 106:727–732. 2012. View Article : Google Scholar : PubMed/NCBI
11	Su X, Zhan P, Gavine PR, Morgan S, Womack C, Ni X, Shen D, Bang YJ, Im SA, Ho Kim W, et al: FGFR2 amplification has prognostic significance in gastric cancer: Results from a large international multicentre study. Br J Cancer. 110:967–975. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhao WM, Wang L, Park H, Chhim S, Tanphanich M, Yashiro M and Kim KJ: Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin Cancer Res. 16:5750–5758. 2010. View Article : Google Scholar : PubMed/NCBI
13	Bai A, Meetze K, Vo NY, Kollipara S, Mazsa EK, Winston WM, Weiler S, Poling LL, Chen T, Ismail NS, et al: GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 70:7630–7639. 2010. View Article : Google Scholar : PubMed/NCBI
14	Sommer A, Kopitz C, Schatz CA, Nising CF, Mahlert C, Lerchen HG, Stelte-Ludwig B, Hammer S, Greven S, Schuhmacher J, et al: Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors. Cancer Res. 76:6331–6339. 2016. View Article : Google Scholar : PubMed/NCBI
15	Chang J, Wang S, Zhang Z, Liu X, Wu Z, Geng R, Ge X, Dai C, Liu R, Zhang Q, et al: Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget. 6:2009–2022. 2015. View Article : Google Scholar : PubMed/NCBI
16	Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C, et al: High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov. 6:838–851. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kim ST, Jang HL, Lee SJ, Lee J, Choi YL, Kim KM, Cho J, Park SH, Park YS, Lim HY, et al: Pazopanib, a novel multitargeted kinase inhibitor, shows potent in vitro antitumor activity in gastric cancer cell lines with FGFR2 amplification. Mol Cancer Ther. 13:2527–2536. 2014. View Article : Google Scholar : PubMed/NCBI
18	Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X, Xu Y, Gao Z, Liu K, Zhou M, et al: FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res. 19:2572–2583. 2013. View Article : Google Scholar : PubMed/NCBI
19	Zhang N, Chang Y, Rios A and An Z: HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin (Shanghai). 48:39–48. 2016.PubMed/NCBI
20	Sithanandam G and Anderson LM: The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther. 15:413–448. 2008. View Article : Google Scholar : PubMed/NCBI
21	Yoshioka T, Nishikawa Y, Ito R, Kawamata M, Doi Y, Yamamoto Y, Yoshida M, Omori Y, Kotanagi H, Masuko T and Enomoto K: Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci. 101:2011–2018. 2010. View Article : Google Scholar : PubMed/NCBI
22	Ema A, Yamashita K, Ushiku H, Kojo K, Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, et al: Immunohistochemical analysis of RTKs expression identified HER3 as a prognostic indicator of gastric cancer. Cancer Sci. 105:1591–1600. 2014. View Article : Google Scholar : PubMed/NCBI
23	Japanese Gastric Cancer Association, . Japanese classification of gastric carcinoma-2nd english edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
24	Nagatsuma AK, Aizawa M, Kuwata T, Doi T, Ohtsu A, Fujii H and Ochiai A: Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer. 18:227–238. 2015. View Article : Google Scholar : PubMed/NCBI
25	Inokuchi M, Murase H, Otsuki S, Kawano T and Kojima K: Different clinical significance of FGFR1-4 expression between diffuse-type and intestinal-type gastric cancer. World J Surg Oncol. 15:22017. View Article : Google Scholar : PubMed/NCBI
26	Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C and Lutterbach B: FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 68:2340–2348. 2008. View Article : Google Scholar : PubMed/NCBI
27	Adachi Y, Oshiro T, Mori M, Maehara Y and Sugimachi K: Prediction of early and late recurrence after curative resection for gastric carcinoma. Cancer. 77:2445–2448. 1996. View Article : Google Scholar : PubMed/NCBI
28	Eom BW, Yoon H, Ryu KW, Lee JH, Cho SJ, Lee JY, Kim CG, Choi IJ, Lee JS, Kook MC, et al: Predictors of timing and patterns of recurrence after curative resection for gastric cancer. Dig Surg. 27:481–486. 2010. View Article : Google Scholar : PubMed/NCBI
29	Choi JY, Ha TK and Kwon SJ: Clinicopathologic characteristics of gastric cancer patients according to the timing of the recurrence after curative surgery. J Gastric Cancer. 11:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
30	Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7:834–846. 2007. View Article : Google Scholar : PubMed/NCBI
31	Tegtmeyer N, Neddermann M, Asche CI and Backert S: Subversion of host kinases: A key network in cellular signaling hijacked by Helicobacter pylori CagA. Mol Microbiol. 105:358–372. 2017. View Article : Google Scholar : PubMed/NCBI